PHAXIAM Provides Business and Financial UpdateFor the First Half of 2023 Conference call and webcast (English) on Monday, September 25,…
NEW YORK, Sept. 21, 2023 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the "Company" or "Y-mAbs") (Nasdaq: YMAB), a commercial-stage biopharmaceutical…
EDISON, N.J., Sept. 21, 2023 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on Artificial…
PALO ALTO, Calif., Sept. 21, 2023 (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, “Scilex” or “Company”), an innovative revenue-generating…
Presentation on Wednesday, October 4th at 02:30 PM PTKANSAS CITY, Kan., Sept. 21, 2023 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ:CING), a…
Mithra to Hold Investor Call on H1 2023 Financial Results on September 26 at 14:00 CEST Liege, Belgium, September 21,…
Information on the total number of voting rights (denominator) Liege, Belgium, 21 September 2023 – 5:45 pm CEST – Mithra…
Debenture proceeds will provide additional funds and flexibility for growthBOUCHERVILLE, Québec, Sept. 21, 2023 (GLOBE NEWSWIRE) -- LSL Pharma Group…
FDA Orphan Drug Designation (“ODD”) qualifies one-time treatment NXC-201 for: 7 years of U.S. market exclusivity after approval Tax credits…
San Diego, California--(Newsfile Corp. - September 22, 2023) - Skye Bioscience, Inc. (OTCQB: SKYED) ("Skye" or the "Company"), a pharmaceutical…